Genital numbness after antidepressants

Genital numbness after antidepressants is a documented effect of SSRIs and SNRIs, and it can begin within an hour of the first tablet. It usually lifts once the medicine stops. But for some people it stays, or only starts after stopping, and by then it is easy to mistake for the depression or anxiety coming back.

Telling the two apart matters. Depression can take away desire, but numbness of the genitals is not a recognised symptom of it: “no mental health disorder causes anaesthesia of the genitals”, write David Healy, who led the 2022 criteria for PSSD (post-SSRI sexual dysfunction), and Dee Mangin. That is why the criteria treat it as the sign that points to the drug rather than the illness.

How genital numbness after antidepressants starts

The authors of the 2022 diagnostic criteria for PSSD, a consensus of 37 doctors and researchers, say a change in genital sensitivity can begin within an hour of the first tablet of an SSRI or SNRI, such as sertraline, escitalopram (Lexapro) or venlafaxine. It may go unnoticed, and they give no measurement of how often it happens.

People describe two kinds of change. Either the genitals feel as if they had been given an anaesthetic, or touch still registers but feels like touch anywhere else.

Since 2019, leaflets for SSRIs and SNRIs in Europe have said that sexual symptoms have in some cases continued after stopping treatment, without saying how often.

For some, the criteria say, a lasting problem may only appear once the tablets stop, or a mild one may get worse. In a 2018 series of reports to RxISK, a drug-safety website, 41 reports on SSRIs and related antidepressants said the problems began or grew much worse after stopping, which is evidence that it happens but not of how often.

Women are in those reports too. Genital numbness came up in 30 of the 50 reports from women, which again shows that it happens, not how often. PSSD in women covers what else they describe.

The symptom depression does not cause

The easiest explanation is the illness itself. In a 2024 paper, Healy and Mangin note reports in the medical literature of patients having their symptoms attributed to “some kind of ongoing mental health condition”. Reports like these cannot say how often that happens.

There is a fair reason for that first thought: depression itself dampens sex. In a 1999 study of 134 people with depression who were not yet taking an antidepressant, over 40% of men and 50% of women reported less interest in sex. The study was small and had no comparison group without depression. Still, a doctor who hears that desire has gone has good reason to think of the illness first.

Numbness is different. “No mental health disorder causes anaesthesia of the genitals, whereas it is a documented effect” of these antidepressants, Healy and Mangin write. In their 2018 series, they add that it is not a feature of anxiety either. These are clinical judgements rather than trial results, so it is fair to ask whether any data point the same way.

Some do. Pirani and colleagues, in a survey led from a Canadian PSSD patient group, analysed answers from 2,179 young people who had taken psychiatric medicines. Among those who had stopped, 93 of 707 past antidepressant users reported lasting genital numbness, against 1 of 102 past users of other psychiatric medicines. The gap held after the researchers allowed for how severe people’s depression was, with odds 14.2 times higher for antidepressants. But the survey only included sexual and gender minority people aged 15 to 29 in the US and Canada, and the numbness was self-reported rather than examined.

Genital numbness that lasted after stopping

Past antidepressant users 93 of 70713.2%

Past users of other psychiatric medicines 1 of 1020.9%

Only one person in the comparison group reported numbness, so the size of the difference is uncertain. The study’s likely range for that 14.2 runs from 2.92 to 257. What the survey does show is a gap that depression severity did not explain.

In the 2022 criteria, a lasting change in genital sensation after stopping is one of only two things that must be present, and the other is having taken the drug. A 2026 review, built on the same criteria rather than new data, says PSSD is told apart from depression returning by “specific somatic symptoms like genital numbness”. Having a mental health diagnosis does not rule PSSD out either.

The side effect the label does not name

In September 2026 we checked the UK prescribing information for doctors for seven SSRIs and SNRIs: escitalopram, sertraline, citalopram, fluoxetine, paroxetine, venlafaxine and duloxetine. All seven carry the 2019 warning. Most list lower sex drive and problems with orgasm or ejaculation, which depression can also bring. None names numbness of the genitals.

Some standard questionnaires for sexual side effects, such as the Arizona Sexual Experience Scale, do not ask about genital sensation either. And the criteria warn that a change in sensation may be hidden beneath lost desire or arousal.

We think these gaps work together. Someone says their interest in sex has gone, which fits depression, and neither the label nor the questionnaire prompts the question that would tell the two apart: has the feeling itself changed? The 2022 authors name the cost: a misdiagnosis as a psychological problem “may result in further use of the causative drug”.

Will the feeling come back?

For most people whose numbness starts on the drug, it lifts once they stop. Sexual effects that start on an SSRI ordinarily lift when treatment stops, though they can linger for some days or weeks. Once a change has lasted three months after stopping, the criteria say PSSD is more likely, though that mark is a consensus rather than a deadline.

Grant is one of the people for whom it did not. After taking escitalopram (Lexapro), he describes emotional numbness and a lack of libido, and how hard it has been to lead a normal life. The criteria note that emotional and genital numbing commonly go together.

One man’s story cannot tell you how often this happens. How many people fully recover has never been properly investigated, and there is no established treatment. David Healy, who led the 2022 criteria, has written that a degree of recovery does appear to happen in some cases over several years. That is an impression, not a count. A count needs people followed for years. The SIDEfxHUB registry follows its members over time, but because they chose to join, it can show how recovery unfolds, not how often it happens.

What to tell your doctor, and where to record it

Low desire fits the illness as well as the drug, so name the change in sensation itself. Have three things ready:

• Say which kind of change it is. Touch may feel dulled, or it may register but no longer feel sexual.
• Say when it began. Rough dates are enough, and it matters whether it started on the drug or after stopping.
• Say what it was like before. The criteria ask for no sign of the same problem before the drug.

Your doctor may not have come across PSSD, and may want to rule out other causes, which the criteria also require. How PSSD is diagnosed explains what to take with you.

Then report it. You do not need a doctor to agree, and you can report years after stopping. Regulators file each report under a term from MedDRA, the medical dictionary they use for side effects, and this condition has its own term.

Depression can take away desire. Numbness is a different signal, and it deserves its own name in the consulting room. If the feeling has changed, say so in those words, report it, and add what happens next to the registry. Nobody has yet counted how often the feeling comes back.

If you are struggling with your mental health, the Samaritans are on 116 123 in the UK, free, at any hour. In the US, call or text 988.